U.S. Machinery Stock News

NasdaqGS:NAVI
NasdaqGS:NAVIConsumer Finance

Is It Time To Reassess Navient (NAVI) After Recent Share Price Slide

If you are wondering whether Navient is priced attractively right now, the recent share moves and current valuation metrics give you quite a bit to think about. The stock recently closed at US$9.81, with returns of an 18.8% decline over 7 days, a 24.5% decline over 30 days, a 23.2% decline year to date and a 24.7% decline over the past year, alongside a 41.1% decline over 3 years and a 3.2% decline over 5 years. These moves have been unfolding against a backdrop of ongoing market attention...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Viavi Solutions (VIAV) Margin Worsening To Q2 Loss Challenges High Growth Narratives

Viavi Solutions (VIAV) has just posted Q2 2026 results with revenue of US$369.3 million and a basic EPS loss of US$0.21, while trailing twelve month figures show revenue of US$1.2 billion and a basic EPS loss of US$0.19. Over recent quarters, the company has seen revenue move from US$270.8 million in Q2 2025 to US$369.3 million in Q2 2026, with EPS shifting from a profit of US$0.04 to a loss of US$0.21 as margins compressed. See our full analysis for Viavi Solutions. With the latest numbers...
NasdaqGS:SILC
NasdaqGS:SILCCommunications

Silicom (SILC) Quarterly Losses Persist Challenging Bullish Profitability Narratives

Silicom (SILC) closed FY 2025 with Q4 revenue of US$16.9 million and a basic EPS loss of US$0.44, alongside net income excluding extra items of a US$2.5 million loss, putting another loss-making quarter on the scoreboard. Over recent periods the company has seen quarterly revenue move from US$14.5 million in Q4 2024 through US$14.4 million in Q1 2025, US$15.0 million in Q2, and US$15.6 million in Q3. Quarterly basic EPS stayed in loss territory, ranging from a US$1.05 loss per share in Q4...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Vera Therapeutics Adds CCO As Atacicept Advances And Valuation Gap Persists

Vera Therapeutics (NasdaqGM:VERA) has appointed Matt Skelton as Chief Commercial Officer. The move comes as the company prepares for potential commercialization of its lead drug, atacicept, for IgA nephropathy. Atacicept has received Breakthrough Therapy Designation and Priority Review from the FDA. Vera Therapeutics focuses on therapies for serious immunologic diseases, with atacicept as its lead asset in IgA nephropathy. The addition of a Chief Commercial Officer signals that management...
NasdaqGS:ETOR
NasdaqGS:ETORCapital Markets

Could New PFOF Rules Quietly Reshape eToro Group’s (ETOR) Core Competitive Edge?

Recent industry attention on eToro Group has focused on how upcoming regulatory changes, including MiFID II amendments, DORA enforcement and a Payment-for-Order-Flow ban, are set to redefine operating standards for digital brokerage platforms. These shifts are expected to raise the bar on transparency, resilience and data connectivity, offering larger players such as eToro an opportunity to deepen user engagement and reinforce trust through stronger compliance and richer account aggregation...
NasdaqGS:AGNC
NasdaqGS:AGNCMortgage REITs

AGNC Balances Strong Returns With More Cautious 2026 Investment Approach

AGNC Investment (NasdaqGS:AGNC) reported robust full-year economic returns for 2025. The company continued its high-yield monthly dividend policy, keeping the payout in double-digit territory. Management outlined a more cautious capital deployment and selective investment approach for 2026. The shift is linked to changing mortgage market conditions, including tighter spreads and prepayment risks. AGNC Investment (NasdaqGS:AGNC) focuses on mortgage backed securities, so shifts in mortgage...
NYSE:MATX
NYSE:MATXShipping

A Look At Matson (MATX) Valuation After Strong Preliminary Q4 Results And Steady 2026 Outlook

Matson’s latest results and dividend decision Matson (MATX) shares are in focus after the company reported preliminary fourth quarter results that surpassed expectations, supported by stronger freight rates and volumes in its China service. See our latest analysis for Matson. Matson’s strong preliminary fourth quarter update and recent dividend declaration come after a sharp 58.79% 90 day share price return. The 5 year total shareholder return of 166.31% points to longer term compounding,...
NasdaqGS:VSEC
NasdaqGS:VSECAerospace & Defense

VSE (VSEC) Valuation Check After Strong Share Price Momentum And Long Term Shareholder Returns

Why VSE (VSEC) Is On Investors’ Radar Today VSE (VSEC) has caught investor attention after a strong recent share price move, with the stock showing solid gains over the month and the past 3 months. This performance has prompted some investors to take a closer look at its fundamentals. See our latest analysis for VSE. That recent momentum sits on top of a longer run, with a 30 day share price return of 26.51% and a very large 5 year total shareholder return of 544.71%. This suggests sentiment...
NYSE:LEA
NYSE:LEAAuto Components

Lear’s New GM T1XX Win Reshapes Future Revenue And Supplier Role

Lear (NYSE:LEA) has secured General Motors' T1XX program at the Orion plant. The program was previously operated by Magna, with Lear set to begin production in 2027. This award represents a shift in supplier responsibilities on a key GM vehicle program. Lear is a major automotive supplier, best known for seating and electronic systems that go into a wide range of vehicles. Winning the GM T1XX program at Orion from a rival supplier puts fresh attention on how automakers are allocating core...
NasdaqGS:KLAC
NasdaqGS:KLACSemiconductor

KLA (KLAC) Net Margin At 35.8% Tests Justification For Premium Earnings Narrative

KLA (KLAC) has just posted Q2 2026 results with revenue of US$3.3 billion and basic EPS of US$8.73, alongside trailing twelve month revenue of US$12.7 billion and EPS of US$34.55 that sit against a 42.1% earnings rise over the past year. Over recent quarters the company has seen revenue move from US$3.1 billion in Q2 2025 to US$3.3 billion in Q2 2026, while quarterly basic EPS shifted from US$6.18 to US$8.73. This sets up the latest report against a backdrop of faster trailing earnings growth...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

Is It Time To Reconsider Progress Software (PRGS) After Its 1 Year Share Price Slump?

If you are wondering whether Progress Software is attractively priced or not, this article will walk through what the numbers are really saying about its current valuation. The stock closed at US$40.92, with returns of 3.6% decline over 7 days, 4.7% decline over 30 days, 0.4% decline year to date, 28.6% decline over 1 year, 26.2% decline over 3 years, and 1.7% gain over 5 years. This gives you a sense of how sentiment around risk and opportunity has shifted over different timeframes. Recent...
NasdaqGM:OLLI
NasdaqGM:OLLIMultiline Retail

Assessing Ollie’s Bargain Outlet Holdings (OLLI) Valuation After Rapid Store Expansion And Solid Same Store Sales

Why Ollie’s recent growth metrics are back in focus Ollie's Bargain Outlet Holdings (OLLI) is drawing fresh attention as investors react to its double-digit annual store growth and steady same-store sales gains. This has raised questions about how the company’s expansion is affecting the current share price. See our latest analysis for Ollie's Bargain Outlet Holdings. At a share price of $110.31, Ollie’s has seen a 2.84% 1 day share price gain. Its 90 day share price return of 8.69% and 1...
NasdaqGS:CORZ
NasdaqGS:CORZSoftware

Core Scientific Refocuses On HPC Leasing As Shareholders Block CoreWeave Deal

Core Scientific (NasdaqGS:CORZ) is shifting its focus from bitcoin mining to high performance computing leasing. The company plans to pursue more HPC colocation contracts starting in 2026. Shareholders recently rejected a proposed merger with CoreWeave, keeping Core Scientific independent. Core Scientific, trading at $17.99, is repositioning itself around HPC leasing while still carrying the legacy of its bitcoin mining roots. The stock has returned 23.6% over the past 30 days and 46.6%...
NasdaqCM:ASTH
NasdaqCM:ASTHHealthcare

Astrana Health (ASTH) Is Down 16.3% After Modest 2027 Medicare Advantage Update Proposal - What's Changed

Astrana Health recently came under pressure after the Centers for Medicare & Medicaid Services proposed only modest payment updates for Medicare Advantage in 2027, raising questions about future revenue tied to these plans. Analysts highlight that Astrana Health’s encounter-driven, risk-adjustment-focused care model could help limit the impact of these proposed policy changes while the company prepares to report its 2025 results in early March 2026. We’ll now look at how the Medicare...
NYSE:DECK
NYSE:DECKLuxury

Deckers Outdoor (DECK) Margin Strength Supports Bullish Narratives Despite Slower Growth Forecasts

Deckers Outdoor Q3 2026 Earnings Snapshot Deckers Outdoor (DECK) just posted Q3 2026 results with revenue of US$1.96b and basic EPS of US$3.34, supported by net income of US$481.1m as the latest read on the business. The company reported revenue of US$1.83b and EPS of US$3.01 in Q3 2025 compared with US$1.96b and EPS of US$3.34 in Q3 2026, while trailing twelve month EPS sits at US$7.03 on revenue of US$5.37b. With a trailing net margin of 19.3%, these numbers keep profitability at the center...